Research programme: botulinum toxin antibodies - Humanyx
Latest Information Update: 22 Feb 2016
At a glance
- Originator Humanyx
- Class Antibodies; Antitoxins
- Mechanism of Action Botulinum toxin inhibitors; Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Botulism
Most Recent Events
- 22 Feb 2016 Preclinical trials in Botulism in USA (Parenteral)